Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Rhea-AI Summary

Vera Therapeutics, Inc. (VERA) will participate in the 6th Annual Guggenheim Biotechnology Conference in New York on February 7th and 8th. The management team will engage in a fireside chat and be available for one-on-one investor meetings.

BRISBANE, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company’s management team will participate in the 6^th Annual Guggenheim Biotechnology Conference, which is taking place in New York on February 7^th and 8^th.

Fireside Chat Details:

Date:	Wednesday, February 7th
Time:	2:00 PM ET

The management team will be available for one-on-one investor meetings. Please contact your Guggenheim representative to request a meeting.

About Vera Therapeutics
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com.

For more information, please contact:

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com

Media Contact:
Mari Purpura
LifeSci Advisors
mpurpura@lifesciadvisors.com

FAQ

When is the 6th Annual Guggenheim Biotechnology Conference taking place?

The conference is taking place in New York on February 7th and 8th.

What is the ticker symbol for Vera Therapeutics, Inc.?

The ticker symbol is VERA.

What will the management team of Vera Therapeutics, Inc. be doing at the conference?

The management team will participate in a fireside chat and be available for one-on-one investor meetings.

How can investors request a meeting with the management team?

Investors can contact their Guggenheim representative to request a meeting.